Tag: BLK

Upside

– $LQDA +41.0% ($380.7M global settlement resolves six lawsuits and preserves uninterrupted YUTREPIA commercialization)

– $TCRT +25.5% (completed Velaris acquisition and secured an approximately $350M private placement to fund development through 2029)

– $VSTM +11.0% (VS-7375 produced a 50% confirmed response rate in eight second-line pancreatic-cancer patients, with FDA alignment on a Phase 3 plan)

– $ENVX +10.0% (received a 100,000-battery drone order and reported preliminary Q3 revenue above guidance)

– $BLK +5.0% (Q3 beat as $205B of net inflows and strong organic base-fee growth topped expectations)

– $ACN +4.0% (investor day targets)

Downside

– $BMEA -20.0% (Phase 1 BMF-650 weight-loss data disappointed investors despite no severe or serious treatment-emergent events)

– $STT -8.5% (Q3 EPS was roughly in line, but revenue missed and fee revenue declined sequentially)

– $FAST -4.5% (Q3 revenue came in slightly light and the 2026 device-signings target was trimmed despite an EPS beat and better operating margin)

– $BAC -4.5% (Q3 adjusted EPS and revenue missed as a $1.2B regulatory-settlement charge weighed on results)

– $HPE -4.5%, NTAP -4.0%, DELL -3.0% (Barclays downgrades the hardware names to Equal Weight, citing valuation and a lack of meaningful AI-driven growth inflection)

– $CRWV -4.0% (no clear fresh company-specific catalyst identified; unusually large premarket move)

Position: None